Lake Forest, Ill.-based Hospira has voluntarily recalled one lot of Lidocaine HCl Injection, USP, 2%, a local anesthetic, due to particles floating in the solution.
If administered, the particle could either block the passage of the solution to the patient and delay therapy or pass from the catheter into the patient, causing local inflammation.
The news release notes the particle is reddish-orange in color. If this color is due to a presence of iron in the particle, it poses a risk to the patient if undergoing an MRI because the particle could be pulled through tissue from the magnetic connection.
The recalled expired lot is Lot 32-135-DD with the expiration date of Aug. 1, 2015.
More Articles on the FDA:
FDA, European Medicines Agency to Collaborate on Generic Drug Approvals
FDA, CMS Extend Parallel Review Program
FDA Names GS1 First Accredited Issuing Agency for UDIs